

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



27 JAN 2005

(10) International Publication Number  
WO 2004/013276 A2

(43) International Publication Date  
12 February 2004 (12.02.2004)

PCT

(51) International Patent Classification<sup>7</sup>:

C12N

(71) Applicants and

(21) International Application Number:

PCT/IB2003/003681

(72) Inventors: PRASSLER, Josef [DE/DE]; Sandstr. 20, 82110 Munich (DE). STARK, Yvonne [DE/DE]; Ho-fangerstr. 10, 81735 Munich (DE).

(22) International Filing Date: 30 July 2003 (30.07.2003)

(81) Designated States (national): AU, CA, US.

(25) Filing Language: English

Published:

(26) Publication Language: English

— without international search report and to be republished upon receipt of that report

(30) Priority Data:  
60/399,150 30 July 2002 (30.07.2002) US

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(71) Applicant (for all designated States except US): MOR-PHOSYS AG [DE/DE]; Lena-Christ-Str. 48, 82152 Martinsried/Planegg (DE).



WO 2004/013276 A2

(54) Title: NOVEL TRICISTRONIC VECTORS AND USES THEREFOR



(57) Abstract: A tricistronic vector (i.e., a vector capable of expressing three exogenous genes, which are not fused together, under the control of one promoter) effectively can encode an immunoglobulin-presenting polypeptide and two immunoglobulin (Ig) polypeptides. The encoded Ig-presenting polypeptide is able to associate with at least one of the Ig polypeptides via co-expressed associating agents. A vector according to the present invention particularly is suited for phage display technology, e.g., when the Ig-presenting polypeptide is a phage coat protein and the Ig polypeptides associate to form a Fab.

## **Novel Tricistronic Vectors and Uses Therefor**

This application claims priority to U.S. provisional application serial number 60/399,150 filed July 30, 2002. The entirety of this application is hereby expressly  
5 incorporated by reference.

### **Background of the Invention**

#### **Field of the Invention**

The field of the invention relates generally to the expression of recombinant DNA.

10 More particularly, the invention relates to novel vectors (and uses therefor) that can be used to express at least three exogenous genes under the control of a single promoter.

#### **Background**

A persistent problem associated with expression of multiple, individual recombinant polypeptides (i.e. polypeptides that are not fused to each other) via a vector in an expression system is obtaining satisfactory yields of each polypeptide. This is especially true, for  
15 example, when the goal is to express multiple proteins that associate with each other upon expression, where poor yield of one or more of the components will hamper or prevent association of the expressed proteins.

The cloning, transformation and expression efficiencies of a vector typically are  
20 inversely related to its size, and therefore one common strategy for expressing multiple polypeptides in an expression system is to use multiple vectors instead of "overloading" a single vector. This approach has drawbacks, however. For instance, short of employing a selection protocol for each vector, there is no way to determine with certainty that a cell contains each vector. In addition, vector incompatibility can hinder obtaining suitable  
25 expression levels even where there is satisfactory vector uptake by the cells.

A separate approach is to integrate each exogenous gene into a single construct, but under the control of multiple promoters within that construct. This strategy, too, is riddled with disadvantages. For example, obtaining suitable expression requires successful function of multiple promoters, which can be difficult to achieve. Accordingly, there is no way to

5 determine with certainty that a cell contains sufficient levels of each recombinant polypeptide, short of employing a selection protocol for each gene expression product operatively linked to its respective promoter. Furthermore, utilizing one promoter per exogenous gene disadvantageously results in a relatively large vector. Placing all cistrons into a single vector under the control of a single promoter has not been a viable option in

10 nearly all applications, since, *e.g.*, the further a cistron is positioned from its promoter, the less likely is the chance that acceptable expression yields will be obtained for that cistron.

Certain tricistronic vectors are known in the art, however. For example, Burger *et al.*, *Appl. Microbiol. Biotechnol.* (1999) 52: 345-353 reported a tricistronic vector that encoded, in a 5-prime to 3-prime orientation, (i) a murine light chain Ig, (ii) a murine heavy chain Ig-TNF $\alpha$  fusion and (iii) puromycin acetyltransferase (*pac*) as a selective marker. Burger *et al.* stated that the foregoing tricistronic vector was selected because “expression of the selective marker and product are strictly linked” (*id.* at 351, rt. col.).

However, in Burger *et al.*, the non-Ig polypeptide (*i.e.*, *pac*) functioned only as a selection vehicle and, hence, did not otherwise associate or otherwise interact with either the 20 murine light chain Ig or heavy chain Ig-TNF $\alpha$  fusion. Accordingly, Burger *et al.* provides no suggestion that three “structural” polypeptide domains could be expressed in sufficient yields so as to associate or otherwise interact with each other after expression. In other words, the disclosure by Burger *et al.* did not overcome the prejudice in the art against using a tricistronic vector to express three or more polypeptide domains that associate or otherwise

interact with each other subsequent to expression. It is apparent, therefore, that a vector that satisfies these and other drawbacks known in the art is greatly to be desired. The present invention provides such vectors, together with methods for their use.

**Summary of the Invention**

5 Accordingly, it is an object of the invention to provide enhanced expression vehicles for generating at least three polypeptide molecules that can interact with each other subsequent to expression.

It is a further object of the invention to provide enhanced expression vehicles that are compatible with a variety of prokaryotic hosts.

10 It is still a further object of the invention to provide methods of using the foregoing expression vehicles to discover new and improved therapeutics for treating disease.

These and other objects are made possible with reference to the teachings contained herein.

In one aspect, the invention provides a tricistronic vector construct that comprises a  
15 prokaryotic promoter, a first nucleic acid sequence encoding an immunoglobulin-presenting polypeptide, a second nucleic acid sequence encoding a first immunoglobulin (Ig) polypeptide, a third nucleic acid sequence encoding a second Ig polypeptide; a first associating agent fused to or comprised within said Ig-presenting polypeptide, and a second associating agent fused to or comprised within said first Ig polypeptide. The first, second and  
20 third nucleic acid sequences are under the control of said promoter and, upon expression of the tricistronic vector, the Ig-presenting polypeptide and the first Ig polypeptide associate via their respective associating agents and the first and second Ig polypeptides self-associate.

The vector may optionally be a phagemid vector.

In one embodiment, the Ig-presenting polypeptide may be a phage coat protein, for example, a gIII protein or a functional fragment of a gIII protein. The gIII functional fragment may contain an N-terminal domain of gIII.

In another embodiment, the first and second Ig polypeptides self-associate to form a  
5 Fab or other functional Ig fragment, for example via a disulfide bond. The first and/or second associating agent may be a cysteine residue.

In still another embodiment, the first and second Ig polypeptides self-associate via non-covalent interactions.

In other embodiments, the vector contains (i) a first secretory signal sequence in the  
10 same reading frame as the nucleic acid sequence encoding the first Ig polypeptide, and/or a second secretory signal sequence in the same reading frame as the nucleic acid sequence encoding the second Ig polypeptide, and/or a third secretory signal sequence in the same reading frame as the nucleic acid sequence encoding the Ig-presenting polypeptide. The first, second and third secretory signal sequences may be prokaryotic signal sequences. The vector  
15 may further contain a ribosome binding site positioned 5-primeward of any or all of the nucleic acid sequences encoding the second Ig polypeptide, the first Ig polypeptide and/or the Ig-presenting polypeptide.

In still further embodiments, the associating agents become disassociated in solution upon the addition of a reducing agent. Alternatively, the second associating agent is fused to  
20 said first Ig polypeptide via a peptide linker.

The following text provides a more detailed, but non-limiting description of the present invention.

### Brief Description of the Figures

**Figure 1** is a schematic depiction of principal components of an inventive tricistronic vector, *i.e.*, a single promoter, an Ig-presenting polypeptide, and two Ig polypeptides.

Abbreviations: Lac p/o lac promoter operator region; SS gpIII signal sequence, gIII phage gene III;

5 RBS Ribosomal binding site; ompA outer membrane protein A signal sequence; phoA alkaline phosphatase signal sequence; L-His6 PGGSGH6 linker.

**Figure 2A** is a vector map of an illustrative vector according to the present invention.

**Figure 2B** provides the nucleic acid sequence for the vector described in **Figure 2a**.

**Figure 3** is a gel that represents a quantitative analysis (by anti-gIIIp Western blot) of  
10 the mean display rate of Fab on the surfaces of phage .

**Figure 4A** is a gel that represents the display rate of a monocistronic scFv vector  
(pMORPH13) encoding scFvs from a VL- $\lambda$  pool (conventional display).

**Figure 4B** is a gel that represents the display rate of a monocistronic scFv vector  
(pMORPH13) encoding scFvs from a VL- $\kappa$  pool (conventional display).

15 **Figure 4C** is a Vector map for pMorph13 scFv Mac1-5

**Figure 4D** is the nucleic acid sequence for pMorph13 scFv Mac1-5

**Figure 5A** is a gel that represents the display rate of a dicistronic scFv vector  
(pMORPH20) encoding scFvs from a VL- $\lambda$  pool (display via Cys residues).

20 **Figure 5B** is a gel that represents the display rate of a dicistronic scFv vector  
(pMORPH20) encoding scFvs from a VL- $\kappa$  pool (display via Cys residues).

**Figure 5C** is a Vector map for pMorph20 Mac1-5

**Figure 5D** is the nucleic acid sequence for pMorph20 Mac1-5

**Figure 6A** is a gel that represents the display rate of a dicistronic Fab vector  
(pMORPH18) encoding a Fab of framework combination VH2  $\lambda$ -1; (conventional display).

- Figure 6B** is a gel that represents the display rate of a dicistronic Fab vector (pMORPH18) encoding a Fab of framework combination VH3 κ-1; (conventional display).
- Figure 6C** is a Vector map of pMORPH<sup>®</sup>18-Fab Mac1-5
- Figure 6D** is the nucleic acid sequence for pMORPH<sup>®</sup>18-Fab Mac1-5
- 5       **Figure 7A** is a gel that represents the display rate of a dicistronic Fab vector, using a two-vector system (pMORPHX10 & pBR\_C\_gIII) and encoding a Fab of framework combination VH3 κ-1, respectively (display via Cys residues).
- 10      **Figure 7B** is a gel that represents the display rate of a dicistronic Fab vector, using a two-vector system (pMORPHX10 & pBR\_C\_gIII) and encoding a Fab of framework combination VH2 κ-1, respectively (display via Cys residues).
- Figure 7C** is the vector map for pMORPHX10 Fab Mac1-5 VL LHC VH FS
- Figure 7D** is the nucleic acid sequence for pMORPHX10 Fab Mac1-5 VL LHC VH FS
- Figure 7E** is the vector map for pMORPHX10 Fab Mac1-5 VL VH LHC
- 15      **Figure 7F** is the nucleic acid sequence for pMORPHX10 Fab Mac1-5 VL VH LHC
- Figure 7G** is the vector map for pBR-C-gIII
- Figure 7H** is the nucleic acid sequence for pBR-C-gIII
- Figure 8A** is a gel that represents the display rate of a tricistronic Fab vector (pMORPH23) encoding a Fab pool (framework combinations VH3 κ/λ).
- 20      **Figure 8B** is a gel that represents the display rate of a tricistronic Fab vector (pMORPH23) encoding a Fab pool (framework combinations VH3 κ/λ).

**Figure 9** is a bar graph comparing the functionality and the binding efficiency of Fab-presenting phage of (i) dicistronic Cys display vectors (2-vector system), (ii) tricistronic Cys display vectors, and (iii) dicistronic conventional display vectors in phage ELISA.

### Detailed Description

The present invention provides novel tricistronic vectors that are useful in multiple contexts. The inventors surprisingly found that tricistronic vectors may be constructed to express three polypeptide molecules in a suitable yield under the control of a single promoter, 5 with the additional feature that the expressed polypeptide domains can maintain function and interact with each other. Another surprising was the observation that all three polypeptides could be exported to the periplasm of a prokaryotic host following expression in the host's cytosol/cytoplasm, and that the expressed polypeptides could interact or otherwise associate in the periplasmic space. Vectors according to the present invention are suitable for use in a 10 number of prokaryotic expression systems.

#### **A. Components of a Vector of the Invention**

The components of a tricistronic vector of the present invention include: (i) nucleic acid sequences encoding three polypeptide molecules (non-fused to each other) and (ii) a single promoter that controls expression of all three polypeptides. The polypeptide-encoding 15 nucleic acid sequences encode, for example, (i) an immunoglobulin (Ig)-presenting polypeptide domain, (ii) a first Ig domain, and (iii) a second Ig domain. In addition, a vector of the invention preferably contains a ribosome binding site 5'-ward of each of the foregoing polypeptide molecules, which can enhance expression levels. Upon expression, the two Ig domains associate to form a functional immunoglobulin fragment, which further associates 20 with the Ig-presenting domain, thereby permitting, for example, display of the functional immunoglobulin fragment on the surface of a filamentous phage.

A vector of the invention may optionally contain nucleic acid sequences encoding at least two associating agents, one of which can be fused to (or comprised within) the Ig-presenting polypeptide; and the other of which can be fused to (or comprised within) the first

Ig polypeptide or second Ig polypeptide. Preferably, subsequent to expression of the vector, the Ig-presenting polypeptide and an Ig polypeptide interact with each other via their respective associating agents, and the two Ig polypeptides associate, e.g., by self-association, hydrogen bonding, van der Waals forces, or via an associating agent(s). The foregoing 5 interaction and association interaction and association preferably occur in the periplasm of the prokaryotic host; however, the invention also contemplates association and interaction in the host's cytosol.

a. **Promoter:**

As used herein, a "promoter" for use in a tricistronic vector of the invention is a 10 promoter that is capable of driving the expression of (i.e. that is functionally linked to) a nucleic acid construct that encodes at least three independent polypeptide molecules (e.g., an Ig-presenting domain and two Ig domains), where those polypeptides are not expressed as fusion proteins with each other. Suitable promoters for use in the invention include, but are not limited to, the lac/operon promoter, CMV promoter P<sub>bad</sub>, P<sub>tet</sub>, P<sub>ara</sub>, P<sub>ADH1</sub>, P<sub>GAL</sub>, P<sub>EF-1α</sub>, 15 P<sub>Sv40</sub>, EM-7 promoter, P<sub>TEF1</sub>, P<sub>RSV</sub>, P<sub>UbC</sub>.

Prokaryotic promoters of the invention can be either constitutive or, more preferably, regulatable (i.e., inducible or derepressible). Further examples of suitable prokaryotic promoters include promoters capable of recognizing the T4 (Malik *et al.*, *J. Biol. Chem.* (1984) 263:1174-1181; Rosenberg *et al.*, *Gene* (1987) 59:191-200; Shinedling *et al.*, *J. 20 Molec. Biol.* (1987) 195:471-480; Hu *et al.*, *Gene* (1986) 42:21-30), T3, Sp6, and T7 (Chamberlin *et al.*, *Nature* (1970) 228:227-231; Bailey *et al.*, *Proc. Natl. Acad. Sci. (U.S.A.)* (1983) 80:24:2814-2818; Davanlook *et al.*, *Proc. Natl. Acad. Sci. (U.S.A.)* (1984) 81:2035-2039) polymerases; the P<sub>R</sub> and P<sub>L</sub> promoters of bacteriophage lambda (THE BACTERIOPHAGE LAMBDA, Hershey, A. D., Ed., Cold Spring Harbor Press, Cold Spring Harbor, N.Y. (1973);

- LAMBDA II, Hendrix, R. W., Ed., Cold Spring Harbor Press, Cold Spring Harbor, N.Y. (1980)); the trp, recA, heat shock, and lacZ promoters of *E. coli*; the  $\alpha$ -amylase (Ulmanen *et al.*, *J. Bacteriol.* (1985) 162:176-182) and the  $\Sigma$ 28-specific promoters of *B. subtilis* (Gilman *et al.*, *Gene* (1984) 32:11-20); the promoters of the bacteriophages of *Bacillus* (Gryczan, T. J., In: THE MOLECULAR BIOLOGY OF THE BACILLI, Academic Press, Inc., NY (1982)); Streptomyces promoters (Ward *et al.*, *Mol. Gen. Genet.* (1986) 203:468-478); the int promoter of bacteriophage lambda; the bla promoter of the  $\beta$ -lactamase gene of pBR322, and the CAT promoter of the chloramphenicol acetyl transferase gene of pBR325, etc. Prokaryotic promoters are reviewed by Glick, B. R. (*J. Indust. Microbiol.* (1987) 1:277-282);
- 10 Cenatiempo, Y. (*Biochimie* (1986) 68:505-516); Watson, J. D., (In: MOLECULAR BIOLOGY OF THE GENE, 4th Ed., Benjamin/Cummings Publishing Co., Inc., Menlo Park, Calif. (1987)); Gottesman, S. (*Ann. Rev. Genet.* (1984) 18:415-442)). Other prokaryotic promoters that may be used include other *E. coli* promoters (Harley *et al.*, *Nucl. Acid Res.* (1987) 15:2343-2361), and Streptomyces promoters (Strohl, *Nucl. Acid Res.* (1992) 20:961-974) for use in
- 15 Streptomyces species expression hosts. All of the foregoing references are incorporated by reference.

b. Immunoglobulin-presenting polypeptide:

An "immunoglobulin-presenting" or "Ig-presenting" polypeptide or polypeptide domain, as used herein, is a (poly)peptide or protein/polypeptide domain that can interact with at least one immunoglobulin polypeptide, such that the immunoglobulin(s) are able to specifically bind, or are involved in the process of specifically binding, an antigen. An Ig-presenting polypeptide preferably interacts with an Ig domain via an associating moiety that customarily is fused to (or contained within) the Ig-presenting domain.

Suitable Ig-presenting domains include a phage coat (capsid) protein, for example a filamentous phage coat protein. A suitable phage coat protein can be, for example, gene III protein (gIIIp), gene VI protein (gVIp), gene VII protein (gVIIp), gene VIII protein (gVIIIp), and gene IX protein (gIXp). A preferred phage coat protein is gIIIp. A phage coat protein

5 may be either a wild type or a modified protein. A "wild type phage coat protein" refers to any protein forming the phage coat of a naturally occurring bacteriophage. The sequences of the foregoing phage coat proteins (including the differences between the closely related members of the filamentous bacteriophages such as f1, fd, and M13) are well known to those of skill in the art (see, e.g., Kay *et al.*, 1996). The skilled artisan will recognize that other Ig-

10 presenting domains are suitable for use in the present invention.

An Ig-presenting polypeptide of the invention also may be a truncated or modified variant of a phage coat protein (e.g., the C-terminal domain of gIIIp). In this regard, a "truncated" or "modified" variant (or a functional fragment thereof) refers to any phage coat protein that has been modified by deleting, inserting and/or substituting at least part of the

15 wild type sequences. Examples of such variants include truncated gene III protein variants that have been found in bacteriophage mutants (see, for example, Crissman & Smith, 1984) or that have been generated for use in phage display methods (e.g. Bass *et al.*, 1990; Krebber, 1996).

The invention also contemplates the use of other Ig-presenting polypeptides. An Ig-

20 presenting polypeptide also may be a green fluorescent protein (gfp), any protein of the cell surface or of the cell wall of bacterial cell, or any protein of a bacteriophage or virus coat.

**c. Immunoglobulin or "Ig" polypeptide or domain**

An "immunoglobulin" or "Ig" polypeptide or domain hereby is defined as a domain of the protein class IgG, IgM, IgE, IgA, and IgD (and any subclass thereof), and includes all

conventionally known antibodies and functional fragments thereof. A "functional fragment" refers to a fragment of an immunoglobulin which retains the antigen-binding moiety of an immunoglobulin. A preferred class of immunoglobulins for use in the present invention is IgG. More specifically, an immunoglobulin domain of the invention can include the domain 5 of (i) a F(ab')<sub>2</sub>, fragment, or (ii) a Fab fragment. The F(ab')<sub>2</sub>, or Fab may be engineered to minimize the intermolecular disulphide interactions that occur between the C<sub>H1</sub> and C<sub>L</sub> domains. An Ig polypeptide may have an amino acid sequence derived from that of an antibody isolated from nature or derived from a natural source, or may have a sequence that is designed *in silico* and encoded by a nucleic acid that is synthetically created. *In silico* 10 design of an antibody sequence can be achieved, for example, by analyzing a database of sequences and devising a polypeptide sequence utilizing the data obtained therefrom. Methods for designing and obtaining such *in silico*-created sequences are described, for example, in U.S. Patent No. 6,300,064 to Knappik *et al.*, which hereby is incorporated by reference in its entirety.

15 A tricistronic vector of the invention preferably encodes two Ig polypeptides that interact with each other and form a functional (antigen-binding) molecule. Interaction between the two Ig polypeptides typically is mediated by residues that belong to each Ig polypeptide. To this end, the first and second polypeptide can comprise heavy and light chain regions of an antibody that associate via non-covalent interactions between 20 corresponding heavy and light chain domains, such as between VH and VL in an Fv fragment, or between VH/VL and CH1/CL in a Fab fragment. Additionally, heavy and light chain regions of an antibody may associate by forming disulphide bonds between the two chains, such as is possible in a Fab fragment. The present invention specifically contemplates the interaction of two Ig polypeptides by mechanisms other than formation of one or more

inter-chain disulfide bonds, e.g., via a linker moiety that is non-covalently attached to at least one of the Ig domains, via hydrogen bonds, via van der Waals interactions, or via peptidic association domains fused to the Ig polypeptides, such as described in U.S. Patent No. 6,294,353 to Pack et al., which hereby is incorporated by reference.

5 An "associating agent" for use in the present invention is defined as an agent that can bring about the interaction between expressed Ig-presenting and Ig polypeptides. An expressed associating agent of the invention is fused to, or comprised within, an Ig-presenting polypeptide and a complementary associating agent is fused to, or comprised within, an Ig polypeptide. The foregoing associating agents may be two different agents, or may be two  
10 identical or substantially identical agents. An associating agent according to the invention preferably contains a cysteine residue that is available for the formation of an intermolecular disulphide linkage.

Preferably, the associating agents are selected so that they do not interfere with the desired function of the fully associated protein complex. Typically, therefore, the associating  
15 agents are suitable amino acid residues that are located outside the region(s) deemed to be responsible for a putative function of the (poly)peptide/protein of interest such as binding to a target. For example, a cysteine residue that is intended to form an inter-chain disulfide bond is positioned at, or in the vicinity of, either the N- or the C-terminus of a polypeptide.

Other suitable associating agents include those which (i) can be fused to the C-terminal end of an Ig polypeptide (or within about 15 amino acid residues thereof) and (ii) can interact with an associating agent fused to or comprised within an Ig-presenting polypeptide. Likewise, suitable agents include any which (i) can be fused N-terminally to (or comprised within) an Ig-presenting polypeptide (e.g., phage coat protein) and (ii) can interact

with an associating agent fused to or comprised within an Ig polypeptide. A specific example of a pair of associating agents in this regard is an avidin-biotin complex..

In the context of the present invention, a cysteine residue is "available for the formation of an intermolecular disulfide bond" if the residue is (i) located N-terminal, C-terminal, or internal to a polypeptide and (ii) accessible for the formation of a disulfide bond with a second residue of the same or different kind. This includes cysteine residues that are buried, and thus not accessible in the "final" polypeptide molecule, but which are accessible in an intermediate compound formed in the course of expression, processing and/or transport in a host cell.

10 In one embodiment, two associating agents may associate, or attach, by the formation of a disulfide bond between (i) at least one cysteine residue present in an Ig polypeptide and (ii) a second cysteine residue present within an Ig-presenting domain that is a wild type phage coat protein. In the case of filamentous bacteriophage fd, for example, wild type proteins contain the following cysteine residues: Cys7, Cys36, Cys46, Cys53, Cys188, Cys201, Cys354, and Cys371 of protein III; residue Cys84 of protein VI; residue Cys22 of protein VII; residue Cys16 of protein IX. Any one or more of these residues may act as an associating agent.

A tricistronic vector of the invention also may contain one or more ribosome binding sites. A ribosomal binding site (Shine-Dalgarno sequence) is a purine rich sequence that in 20 on bacterial mRNA is located about ten nucleotides 5'-primeward of the initiator codon for a particular polypeptide. A Shine-Dalgarno sequence is involved in the binding of the ribosome and the mediating of efficient translation of the respective gene.

A tricistronic vector of the invention also may contain one or more nucleic acid sequences that encode a signal or secretory polypeptide. A "signal" or "secretory"

polypeptide hereby is defined as a polypeptide responsible for transporting another polypeptide from bacterial cytosol to bacterial periplasm. A signal or secretory polypeptide of the invention preferably is located N-terminal to the polypeptide to be transported to the periplasm. The use of one or more secretory polypeptides can be especially advantageous in

5 the context of phage display technology, as described, *infra*, whereby the secretory polypeptide (i) is linked to a encoded polypeptide, and (ii) directs the corresponding polypeptide to the periplasmic space of its prokaryotic host cell. Secretory polypeptides include, for example, *ompA* and *phoA*, gene III signal sequence, *st II*, and *pelB*, each of which can be used in a prokaryotic expression system. Other nucleic acid sequences

10 encoding secretory peptide sequences are well known in the art and may also be used in the present invention. In one aspect of the invention, a secretory nucleic acid sequence (*e.g.*, *ompA*) is linked to the nucleic acid sequence that encodes a first Ig domain, while a second secretory nucleic acid sequence (*e.g.*, *phoA*) is linked to the nucleic acid sequence that encodes a second Ig domain. A secretory nucleic acid sequence also can be linked to the

15 nucleic acid sequence that encodes an Ig-presenting polypeptide. Alternatively, the secretory domain can be an inherent property of an Ig-presenting domain of the invention.

A tricistronic vector of the invention also may contain one or more nucleic acid sequences that can encode a “polypeptide linker” that functions to link an associating agent to an Ig-presenting and/or an Ig domain. In this context, the linker can be viewed as a “spacer”

20 between an associating agent and its respective polypeptide. This linker preferably contains about 1-50 amino acids, and preferably 5 to 15 amino acids. Typically, a linker consists of glycine-serine rich stretches, but can also contain other amino acid residues. The size can also be variable according to the purpose of the linker.

A tricistronic vector of the invention also can be constructed so as to contain one or more affinity tags (e.g., His6 tag) that is fused to one of the Ig domains, for example. An affinity tag can be used to purify or isolate a population of Ig molecules bearing this tag.

A tricistronic vector of the invention also can be constructed so as to contain one or 5 more restriction sites that facilitate cloning, sub-cloning, or other manipulation of the vector. For example, when a plurality of restriction sites are present, unique restriction sites can be engineered to flank a particular segment of the vector, thereby making the vector modular. The feature of modularity can be advantageous, e.g., for subsequent modification of the tricistronic vector at one or more discrete positions. According to this approach, a particular 10 segment of the tricistronic vector can be excised and substituted with another desired segment, using convention technology. A library such as the HuCAL antibody library described in U.S. Patent No. 6,300,064 to Knappik *et al.*, is particularly preferred for use in a vector of the present invention.

An illustrative, non-limiting embodiment of a vector according to the invention 15 (pMORPH23) is set forth in Figure 2A. According to Figure 2A, pMORPH23 contains a ColEI origin of replication, a functional origin for single stranded replication, and a chloramphenicol-resistance gene. The tricistronic operon is under the control of an inducible lac promoter/operator region. All functional modules are flanked by unique restriction sites. The first expression cassette contains the signal sequence of geneIII, and the engineered full-length (mature) geneIII sequence with an additional N-terminal cysteine residue. The second 20 expression cassette, which is preceded by a ribosomal binding site (SD-Seq), encodes the light chain of an Ig and contains the bacterial signal sequence ompA followed by VL and CL. The third expression cassette, which is preceded by a ribosomal binding site (SD-Seq), contains a heavy chain Fd (VH1 + CH1) with an additional C-terminal cysteine. The

bacterial signal sequence phoA is followed by VH1 and CH1, whereby a glycine-serine-rich linker and a His6-tag act as a spacer for the introduced cysteine to the Fd chain..

**B. Constructing a Vector of the Invention**

Methods for constructing vectors comprising nucleic acid molecules are known in the art (see, e.g., Sambrook *et al.*, 1989; Ausubel *et al.*, 1994). A vector map of a representative vector of the invention (pMORPH23) is provided in Figure 2A, with its nucleic acid sequence provided in Figure 2B.

**C. Representative Uses of a Vector According to the Invention**

A tricistronic vector of the invention can be used, or can be modified to be used, in a variety of prokaryotic expression systems. A suitable host cell is any cell that permits expression and subsequent interaction of the three principal polypeptide domains (*i.e.*, Ig-presenting and two Ig domains). Methods for introducing vectors into appropriately chosen host cells, and causing or allowing the expression of polypeptides are known in the art (see, e.g., Sambrook *et al.*, 1989; Ausubel *et al.*, 1994).

A vector according to the invention, is particularly suited for expression in an *E.coli* host cell. In this regard, the vector can be in the form of a phagemid vector. A phagemid consists of elements of conventional plasmid vectors (e.g., marker gene, cloned genes, plasmid origin of replication) and of elements of filamentous phage (e.g., gIII, PS and phage *ori*). A phagemid can be introduced into a host cell, and subsequently be cultivated and amplified therein like a plasmid. Phagemid vectors are well known in the art.

A phagemid does not encode all of the genes necessary to permit assembly of viral particles and requires "rescue" in a host cell with a helper phage. The helper phage provides the missing phage genes that permit assembly of the viral particles. It will be appreciated that use of a phagemid/helper phage system an result in production of particles that contain either

the helper phage genome or the phagemid. Methods of preferentially packaging the phagemid are well known in the art, for example by using a helper phage, such as M13 K07 that contains a functional, but defective, DNA origin of replication so that phagemid is preferentially packaged into phagemid particles. Methods for the introduction of genetic material required to produce progeny phage or phagemid particles in appropriate host cells, and for causing or allowing the generation of such particles are well known in the art (see, e.g., Kay *et al.*, eds. (1996) PHAGE DISPLAY OF PEPTIDES AND PROTEINS: A LABORATORY MANUAL. Academic Press, Inc., San Diego).

A vector of the invention can, accordingly, be used to carry out a method for producing a polypeptide or protein having a desired property. This method includes the steps of (i) providing a collection of bacteriophage particles that present on their surface a diverse collection of one or more Ig polypeptides as defined herein; and (ii) screening and/or selecting the diverse collection for at least one Ig domain having the desired property. Here, the term "desired property" refers to a property that (a) one of the polypeptides or proteins out of the diverse collection should have and (b) forms the basis for screening and/or selecting the diverse collection. A property might be the ability to: bind a target, block a target, or activate a target-mediated reaction. A further property may be, for example, enzymatic activity, or any other properties known to those skilled in the art. Methods for identifying suitable experimental formats and for carrying out necessary steps for performing screening and/or selection are well known in the art.

A preferred property of an Ig polypeptide is specific binding to a target. The target can be presented to the diverse collection of bacteriophage particles in a variety of ways well known to one of ordinary skill, for example, by coating on surfaces for solid phase

biopanning, by linkage to particles such as magnetic beads for biopanning in solution, or by display on the surface of cells for whole cell biopanning.

Bacteriophage particles that display (via an Ig-presenting domain) one or more Ig polypeptides (which are bound to a target) can be recovered by a variety of methods well known to one of ordinary skill. If the associating agents link the Ig-presenting polypeptide and Ig polypeptide via a disulfide bond, then the specifically bound Ig-target complexes can be treated under reducing conditions (e.g., incubation with DTT) to cleave the disulfide bonds and to recover the specific bacteriophage particles for further rounds of biopanning and/or for identification of the Ig polypeptide domains specifically binding to said target.

10

### Examples

The present invention can be better understood with reference to the following examples, which are not intended to limit the scope of the invention as described above.

**Example 1: General protocol for quantitative analysis of display of antibody fragments on phage.**

15 The protocol, which also applies to Examples 2-6, was performed according to Johansen, L. K. *et al.* (1995), *Protein Engng.* 8, 10, 1063-1067. Different dilutions of the same phage preparation were subjected to a protein gel. However, in Examples 3, 5 and 7, no reducing agents were added, due to the presence of cysteines as associating agents. The proteins of the protein gel were transferred to a membrane. gIIIp protein on the membrane  
20 was detected by anti-gIIIp antibody (Western blot). Then, one wild-type gene III protein (“wtgIIIp”) band and one band of the antibody-gIIIp linkage, which have the same intensity were analysed. Given (i) the number of phages loaded, (ii) the molar ratio of both proteins, and (iii) the assumption of 5 wtgIIIp-proteins per phage, the mean number of antibody fragments displayed per phage could be calculated. Figure 1 provides expression data of a  
25 dicistronic Fab vector (pMORPH18) using conventional (*i.e.*, gIIIp-fusion) display. The data

indicate a ratio of Fd-gIIIct:wtgIIIp =  $1.25 \times 10^8$  phage: $2 \times 10^7$  phage. This correlates to the presentation of 1 Fd-gIIIct per 6.25 wtgIIIp; in other words, 1 Fd-gIIIct per 1.25 wtgIIIp. Accordingly, the mean number of Fabs per phage in this experiment was 0.8.

Abbreviations throughout: Fd = VH-CH1; Fd-ct = Fd-gIIIct & VH-CH1-gIIIct; g3p =  
5 gIIIp.

**Example 2: Display determination of monocistronic scFv vector, using conventional display**

A protocol as disclosed in Example 1 was carried out for performing a quantitative display analysis of a monocistronic scFv vector (pMORPH13), using conventional phage display.  
10 Figure 4A provides expression data of the (pMORPH13) vector from a VL- $\lambda$  pool; and Figure 4B provides expression data of the (pMORPH13) vector from a VL- $\kappa$  pool. The data indicate a ratio of scFv-gIIIct:wtgIIIp =  $1 \times 10^9$  phage: $6.7 \times 10^7$  phage in Figure 4A, and a ratio of scFv-gIIIct:wtgIIIp =  $5 \times 10^8$  phage: $1 \times 10^7$  phage in Figure 4B. Accordingly, the mean number of ScFv per phage in this experiment was approximately 0.3 and 0.1, respectively.

15 **Example 3: Display determination of a dicistronic scFv vector, using Cys display**

A protocol as disclosed in Example 1 was carried out (except with using reducing agents) for performing a quantitative display analysis of a dicistronic scFv vector (pMORPH20), using Cys display. Figure 5A provides expression data of the pMORPH20 vector from a VL- $\lambda$  pool; and Figure 5B provides expression data of the pMORPH20 vector from a VL- $\kappa$  pool. The data indicate a ratio of scFv-SS-gIIIct:wtgIIIp =  $1 \times 10^{10}$  phage: $4 \times 10^7$  phage in Figure 5A, and a ratio of scFv-SS-gIIIct:wtgIIIp =  $5 \times 10^{9***}$  phage: $2 \times 10^7$  phage in Figure 5B. Accordingly, the mean number of scFv per phage in this experiment was approximately 0.02 and 0.02 respectively.

**Example 4: Display determination of a dicistronic Fab vector, using conventional display**

A protocol as disclosed in Example 1 was carried out for performing a quantitative display analysis of a dicistronic Fab vector (pMORPH18), using conventional phage display.

- 5 Figure 6A provides expression data of the pMORPH18 vector (single Fab of framework combination VH2-λ1); and Figure 6B provides expression data of the pMORPH18 vector (single Fab of framework combination VH3-κ1). The data indicate a ratio of Fd-gIIIct:wtgIIIp =  $1 \times 10^9$  phage:2 $\times 10^7$  phage in Figure 6A, and a ratio of Fd-gIIIct:wtgIIIp =  $1 \times 10^8$  phage:1 $\times 10^7$  phage in Figure 6B. Accordingly, the mean number of Fabs per phage in  
10 this experiment was approximately 0.1 and 0.5, respectively.

**Example 5: Display determination of a dicistronic Fab two-vector system, using Cys display**

- A protocol as disclosed in Example 1 was carried out (except with using reducing agents) for performing a quantitative display analysis of a dicistronic Fab vector in a two-vector  
15 system (pMORPH10 + pBR\_C\_gIII), using Cys display. Figure 7A provides expression data of the pMORPH10 vector system (single Fab of framework combination VH3-κ1); and Figure 7B provides expression data of the pMORPH10 vector system (single Fab of framework combination VH2-λ1). The data indicate a ratio of VL\_CL-SS-gIII:wtgIIIp =  $1 \times 10^9$  phage: $8 \times 10^6$  phage in Figure 7A, and a ratio of VL\_CL-SS-gIII:wtgIIIp =  $8 \times 10^9$  phage: $3 \times 10^7$  phage in Figure 7B. Accordingly, the mean number of Fabs per phage in this experiment was  
20 approximately 0.04 and 0.02, respectively.

**Example 6: Analysis of display rates and efficiency in phage ELISAs**

The following table summarizes approximate display rates obtained in Examples 1-5:

**Table I**

System	Vector(s)	Approximate display rates (Ig per Phage)
scFv conventional (monocistronic)	pMORPH13	0.1 - 0.3
scFv CysDisplay (dicistronic)	pMORPH20	0.02
Fab conventional (dicistronic)	pMORPH18	0.1 - 0.8
Fab CysDisplay (dicistronic)	pMORPHX10 + pBR_C_gIII	0.02 - 0.04

From this table, two trends are understood. First, the display rates decrease as much as 2.5 to 40 fold when using CysDisplay in lieu of conventional display. Second, the display rates decrease as much as 5 to 15 fold when moving from a monocistronic conventional display vector to a dicistronic CysDisplay vector. Accordingly, CysDisplay phage generally showed reduced display rates in comparison to phage containing conventional genetic fusions of antibody fragments to gIII (or gIIIct fragment). Because it would be highly undesirable to work with display rates lower than 0.04 Fabs per phage, the use of a tricistronic Fab vector that additionally was engineered for CysDisplay was thought not to be possible, based on the foregoing trends of decreased display rates.

**Example 7: Display determination of tricistronic Fab vector, using Cys display (single vector system)**

A protocol as disclosed in Example 1 was carried out (except with using reducing agents) for performing a quantitative display analysis of a tricistronic Fab vector (pMORPH23), using Cys display. Figure 8A provides expression data of the pMORPH23 vector from a VH3 +  $\kappa/\lambda$  pool; and Figure 8B provides expression data of the pMORPH23 vector from a VH3 +  $\kappa/\lambda$  pool. The data indicate a ratio of Fd-SS-gIII:wtgIIIp =  $5 \times 10^{10}$  phage: $3 \times 10^9$  phage in Figure 8A, and a ratio of Fd-SS-gIII:wtgIIIp =  $5 \times 10^9$  phage: $1 \times 10^8$  phage in Figure 8B. Accordingly, the mean number of Fabs per phage in this experiment was approximately 0.3 and 0.1, respectively.

As is shown in Table II below, the tricistronic Fab CysDisplay vector (pMORPH23) yield improved Fab display rates when compared to the dicistronic Fab CysDisplay system, which always needs a second vector providing the Cys-gIII construct. When using a constant amount of phage in the foregoing examples, the signals obtained with the tricistronic system 5 were higher than those obtained with the dicistronic system. This indicates an increased display rate with the tricistronic version, which was unexpected.

**Table II**

System	Vector(s)	Approximate display rates (Ig per Phage)
scFv conventional	pMORPH13	0.1 - 0.3
scFv CysDisplay	pMORPH20	0.02
Fab conventional	pMORPH18	0.1 - 0.8
Fab CysDisplay dicistronic	pMORPHX10 + pBR_C_gIII	0.02 - 0.04
<b>Fab CysDisplay tricistronic</b>	<b>pMORPH23</b>	<b>0.05-0.3</b>

10 **Example 8: Comparison of dicistronic and tricistronic Fab Cys Display vectors in phage ELISA**

Phage preparations (i) anti-Mac1 I-domain, (ii) Fab Mac 1-5 and (iii) Mac1\_A8 were expressed from the dicistronic CysDisplay vector (pMORPHX10 + pBR\_C\_gIII; two-vector-system), the tricistronic CysDisplay vector (pMORPH23) and the dicistronic, conventional Fab vector (pMORPH18) and displayed on phage. The phage were concentrated and the titer 15 of the phage preparations was determined.

Maxisorp wells of a microtiter plate were coated with 100 µl Mac1 I-domain protein per well (concentration of the antigen solution in PBS: 50 µg/ml) overnight at 4°C. The antigen solution was removed and the coated wells were washed with PBS. Next, the antigen-coated wells were blocked with 300 µl 5% MPBST for 1 hour at room temperature. 20 At the same time, an aliquot of each phage preparation (100 µl per well; 7.5E+9 phages) 1:1 was mixed with 10% MPBST (incl. 0.1% Tween20). The phage were incubated for 1 hour at

room temperature. The coated wells were washed 3x with PBS. Then, 200 µl of pre-blocked phage solution was transferred into each coated well, and incubated for 1 hour at room temperature. Then, the phage were removed from the wells, and non-bound phage were washed off using PBST and PBS. Next, 100 µl anti-M13-HRP conjugate (1:5000) in 5% MPBST (incl. 0.05% Tween20) was added and incubated for one hour at room temperature. Another PBST and PBS wash was performed, and 100 µl POD-Substrate was added. A measurement at 370 nm was taken after several minutes in order to quantify the amount of anti-Mac1 phage attached to the antigen in the wells.

Figure 9 is a bar graph that compares functionality and binding efficiency (functional Fab display) between dicistronic and tricistronic Fab Cys Display vectors in phage ELISA. The improved binding efficiency of the phage resulting from the tricistronic CysDisplay vector versus the dicistronic CysDisplay vector confirms the data of the increased display rates. Bars 1 and 2 represent independent experiments of the same construct. The first two bars for each group represent experiments performed with Fab molecule Mac1-5; the last two bars for each group represent experiments performed with Fab molecule Mac1\_A8).

**Example 9: Successful Antibody Library Screening using a tricistronic vector system in Cys Display**

Wells of MaxiSorp<sup>TM</sup> microtiter plates (NUNC) were coated with 15 µg per antigen (ICAM-1 protein, rabbit myosin, FITC-BSA, estradiol-BSA) dissolved in PBS. Using a tricistronic vector as described in Examples 2A and 2B in conjunction with proprietary MorphoSys phage display and selection techniques, the results provided in Table III were obtained upon screening a MorphoSys HuCAL® Library.

**Table III**

Antigen	Elution	% primary hits 2 <sup>nd</sup> round	% primary hits 3 <sup>rd</sup> round	No. of consolidated, specific antibodies
ICAM-1 protein	DTT	0%	17%	1
ICAM-1 protein	glycine + TG1	0%	60%	3
myosin	DTT	1%	29%	4
myosin	glycine + TG1	14%	19%	1
FITC-BSA	DTT	82%	100%	6
FITC-BSA	glycine + TG1	92%	87%	6
estradiol-BSA	DTT	75%	67%	6
estradiol-BSA	glycine + TG1	59%	67%	3

The foregoing data confirm that tricistronic vectors of the invention are effective

5 vehicles for expressing, at a minimum, three functional polypeptide molecules.

**Example 10: Construction of pMORPH23 vector**

The vector pMORPH23 described here is a derivative of the pCAL vector series

(WO 97/08320; Knappik *et al.*, 2000), which is a modified version of the dicistronic

10 expression vector pMORPH20 (example 3). A vector map for pMORPH20 is provided in Figure 5C and the related nucleic acid sequence is provided in Figure 5D.

The dicistronic expression vector pMORPH20 was digested with restriction enzymes *StuI* and *MscI*, to remove the scFv-expression module. The resulting blunt end cut vector was religated after agarose gel purification and transformed into competent E.coli cells. The 15 intermediate vector product was further modified by replacing the *ompA* signal sequence (*XbaI* and *EcoRV* digest) by a oligonucleotide cassette preformed by annealing primer pairs A and B coding for the gpIII signal sequence and introducing a 5' *AccI* restriction site and a 3' blunt end.

**Primer A:**

```
ctagtatacg agggcaaaaa atgaaaaaac tgctgttcgc  
gattccgctg gtggtgccgt tctatagcca tagcactac tgcgac
```

**Primer B:**

5 gtcgcagtag tcgctatggc tatagaacgg caccaccaggc  
ggaatcgcgaa acagcagttt tttcatttt tgccctcgta ta

To obtain the final pMORPH23 library cloning vector, an AflII-XbaI-Bla-EcoRI stuffer cassette was introduced by ligation. The stuffer fragment allows efficient cloning of  
10 HuCAL Fab fragments by XbaI and EcoRI. An example for tricistronic pMORPH23-HuCALFab vector is shown in Figure 2A and 2B. All three modules in pMORPH23 are transcribed as one unit from the lac p/o region.

**Claims**

What is claimed is:

1. A tricistronic vector construct comprising:
  - a prokaryotic promoter;
  - a first nucleic acid sequence encoding an immunoglobulin-presenting polypeptide;
  - a second nucleic acid sequence encoding a first immunoglobulin (Ig) polypeptide;
  - a third nucleic acid sequence encoding a second Ig polypeptide;
  - a first associating agent fused to or comprised within said Ig-presenting polypeptide; and
  - a second associating agent fused to or comprised within said first Ig polypeptide,

wherein said first, second and third nucleic acid sequences are under the control of said promoter, and wherein upon expression of said tricistronic vector, (i) said Ig-presenting polypeptide and said first Ig polypeptide associate via their respective associating agents and (ii) said first and second Ig polypeptides self-associate.

2. The tricistronic vector construct according to claim 1, wherein said Ig-presenting polypeptide is a phage coat protein.

3. The tricistronic vector construct according to claim 2, wherein said first and second Ig polypeptides self-associate to form a Fab or other functional Ig fragment.

4. The tricistronic vector construct according to claim 3, wherein said phage coat protein is a gIII protein or a functional fragment thereof.
5. The tricistronic vector construct according to claim 4, wherein said gIII functional fragment comprises an N-terminal domain of gIII.
6. The tricistronic vector construct according to claim 2, wherein said first and second associating agents associate with each other via a disulfide bond.
7. The tricistronic vector construct according to claim 6, wherein the first or second associating agent is a cysteine residue.
8. The tricistronic vector construct according to claim 7, wherein the first and second associating agents are each a cysteine residue.
9. The tricistronic vector construct according to claim 1, wherein the first and second Ig polypeptides self-associate via non-covalent interactions.
10. The tricistronic vector construct according to claim 1, further comprising a first secretory signal sequence in the same reading frame as the nucleic acid sequence encoding the first Ig polypeptide.

11. The tricistronic vector construct according to claim 10, further comprising a second secretory signal sequence in the same reading frame as the nucleic acid sequence encoding the second Ig polypeptide.

12. The tricistronic vector construct according to claim 11, further comprising a third secretory signal sequence in the same reading frame as the nucleic acid sequence encoding the Ig-presenting polypeptide.

13. The tricistronic vector construct according to claim 2, wherein said vector is a phagemid vector.

14. The tricistronic vector construct according to claim 1, wherein the associating agents become disassociated in solution upon the addition of a reducing agent.

15. The tricistronic vector construct according to claim 1, wherein said second associating agent is fused to said first Ig polypeptide via a peptide linker.

16. The tricistronic vector construct according to claim 12, wherein said first, second and secretory signal sequences are prokaryotic signal sequences.


17. The tricistronic vector construct according to claim 1, further comprising a ribosome binding site positioned 5'-primeward of the nucleic acid sequence encoding the second Ig polypeptide.

18. The tricistronic vector construct according to claim 17, further comprising a ribosome binding site positioned 5-primeward of the nucleic acid sequence encoding the first Ig polypeptide.

19. The tricistronic vector construct according to claim 18, further comprising a ribosome binding site positioned 5-primeward of the nucleic acid sequence encoding the Ig-presenting polypeptide.



**Figure 1:**



**Figure 2 A: Vector map pMorph23 anti-EsB Fab**

**Figure 2 B DNA sequence of pMorph23 anti-EsB Fab**

XbaI	HuCAL Primer #3 100.0%		EcoRV
1	CTAGATAACG ACGGCAAAAA ATGAAAAAAGA CAGTATCGC GATIGCA GTG GCACTGGCTG GJTCGCTAC CGTAGCGCAGGCCGATATCG TGCTGACCCA		
101	GATCTATTGCTCCCGTTTTCT TACTTTCTCT CGTCGATAGCG CTAACTGCAC CGTGTGGCTG CAAGCGATG GCATCGCGT CGCTATAGC AGGACTGGGT		
201	GAGCCCGCG ACCTGAGCC TGTCTCGGG CGAACCTGCGACCGCTGAGCT CGAGAGGAG CGAGCTGTTCTCGTCTT ATCTGGCTTG GTACCAAGCG		
	CTCGGGCCCG TGGGACTCGG ACAGAGGCC GCTTGACCC TGGGACTCGA CGTCCTCCCT CGTCAGACAA AGAGCAAGAA TAGACCGAAC CATGGTCGTC		
	AAACCAAGCT AAGCACCGGC TCTTAAATT TATGGTGTCT CTGGTGTGCA ACTGGGGTC CGGCGCGT TTAGCGCGTC TGGATCCCGC ACGGATTTA		
	TTGGTCCAG TTCTGGGC AGATAATTAATACACAGA GAGCAACAG TTGACCCAG GGCGCGCAA ATCGCGAG ACCTAGGGCG TGCTAAAT		
BssI			MscI
301	CCCTGACCAT TAGCAGCCCTG GAACCTGAAG ACTTTGCGAC TTAAATTGCA CAGCAGCTG GTAATTATTC TATTACCTT GGCCAGGGTA CGAAAGTTGA		
	GGGACTGGTA ATCGTCGGAC CTGGACTIC TGAAAAGCTG ATAATAACGGTGTGCA CATTAAATAAG ATAATGAAAACCGTCCCAT GCTTCAACT		
BstWI			
401	ATTAACACG ACGGTGGCTG CTCCGAGCGT GTTTATTTT CGCGCGAGCG ATGAACAATC GAAAAGCGC ACGGCGAGCG TGGTGTGCT GCTGAAACAC		
501	TTAATTGCA TGCCGAC GAGGGCGCA CAAATAAAAAGGCGCTG CGACTTGTG CTGGCTCG ACCACACGGG CGACTTGTG		
601	TTTATCCC GTGAAGCGA AGTTCAGTG AAAGTAGACA CGCGCTGCA AAGGGCAC ACGGAGAAA CGCTGACCA AGAGGATAAC AAAAGATAGCA		
	AAATAAGCG CACTTCGCTTCAAGTCACC TTTCATCTGT TGCGAACGT TTGCGCGT TGCGTCTT CGCACTGGCT GTCCTATCG TTCTATCGT		
	CCTATCTCT GAGCACCCCT CGACCCCTG AATAGAAAACATAAAAGTGT ATGCGTGCAGA ATGACCCCA CAAGGTCGTA CGAGCCGGT		
	GGATAAGAGA CTCTGCTGG GACTGGACT CGTTTCGCTT AATACCTTTT GTATTTCACA TACGCACGCT TCACGGGTA GTTCCAGACT CGTCGGGCCA		
HuCAL for 100.0%			
SstI	SphI	SapI	
	HuCAL Primer #1 100.0%		
701	GACTAAATCT TTAAATCGTG GCGAGGCCG AATAGCATGC GTAGGAGAAA ATAAAAAGAA ACAAAAGCACT ATTGCACTGG CACTCTTACG GTTGCTCTTC		
	CTGATTAGA AAATAAGCA CGCTCGGACTATTCTGACG CATCCTCTT TATTTCACI TGTTCTGTA TAACGTGACC GTGAAGATGG CAACGAGAAG		
HuCAL for 100.0%			MscI
801	ACCCGTTTA CCAAAGCCCA GTGTCATTG GTGGAAGCG CGGGCGGCCCT GGTGCAACCGGGCGCA CGC TGCGCTGAG CTGCGGGGCC TCGGAGTTA		
901	TGGGACAAAT GTTTTCGGGT CCACGTTAAC CACCTTCGC CGCCCCCGGA CCACGTGGC CGCGCGTGG ACACGACTC GACGCCCGG AGGCCAAAT		
1001	CTCTTCTCCTTCTTATGGTGTGAA TTGGTGTGCGCAAGCCCGGCTT CGGGCGGGG ACCTTCGCA GAGCTCACAC CCTACGATCTA CCTTATATGCG		
	GGAAAAGAG AATACCCCA TTAAACCCAG CGGGCGGGG ACCTTCGCA GAGCTCACAC CCTACGATCTA CCTTATATGCG		
	GGATAACCGTGA AGGGCGTTT TTACCATTC ACGTGATAAT CGAAAACACA CCTGTATCT GCAAATGAC ACCTCGCGTG CGGAAGATAC CGCCGTGTAT		
	CCTATCGCAC TTCCGGCAA AATGGTAAAG TGCACTTAA AGCTTTGTG GGGACATAGA CGTTTACTTG CGGACGACAC GCCTTCTATG CGGCCACATA		
	Sall		
BssHII	SapI	StyI	BpuI
	HuCAL rev 100.0%		
1101	TATTGCGCG GTGCTCTTC TAAGTGGCT GTTGTGGTTT TGATCATTG GGGCAAGGC ACCCTGGTA CGGTTAGCTC AGCGTCGACC AAAGGCCAA		
1201	ATAACGCCGACAGAGAT ATTCAACCGA CCAACCCCAA AACTAGTAAAC CGCGTTCCG TGGGACCACT GCCAATCGAG TCGCAGCTGG TTCCAGGT		
1301	GGGTGTTCCCGCTCCGAGCAGCAAGCCAA GCACAGCGG CGGCACGGCT GCGTGGTTA AGATATTCTC CGGGAACCGAG TCAAGTGTGAG		
	CGCACAAAGG CGACCGAGGC TGCTGCTTTT CGTGTGCGCC CGCGCGCGA CGGACCGCAATT CCTAATAAG CGCCTTGGTC AGTGGCACTC		
	CTGGAACACCGGGGGCGCTGA CGACGGCGCTGAC TCGATCTT CGGGGGGTGCG TGCAAAGCGAG CGGCCCTGAT AGGCTGAGCA CGTGGCCGAC		
	GACCTTGTGG CCCCGGACT GTTCGCCCCA CGTATGGAAA CGGCCGCA CG ACCTTGTGCG CGCCGACATA TCGGACTCGT CCTAACACTG GCACGACTCG		
	EcoRI		
1401	ACGAGCTTAG GCACTCAGACCTATATTG AACGTGACCACTAAACCGAG CAACACCAA GTGGATAAAA AAGTGGACCC GAAAAGCGAA TTCCCAGGG		
	TCGTCGAAATC CGTGTGCTG GATAAAACG TTGCACTTGG TATTTGGCTC GTTGTGGTTT CACCTATTTT TTACCTTGG TTTCGCTT AAGGGCCCC		
BssHII			
1501	Ascl	HindIII	
	HuCAL rev 100.0%		
1601	GGAGCGGAGG CGCGCCGAC CATCATACCACTACTGCTG ATAAGCTTGA CCTGTGAAGT GAAAATGGC GCAGATTG TGCGACATTGTT TTGCTGCG		
1701	CTCTCGCTCC CGCGCGCTCG GTAGTAGTGG TAGTGCAGCACT TGGACACTTCA CTTCCTACCG CGTCAACAC GCTGTGAAA AACAGACGG		
1801	GTTTAATGAAAATTGAAACG TTAAATTTTC CGGTAAATT TTGTTAAAT CAGCTCATTT TTAACACCAAT AGGCCGAAT CGCCAAAATC		
1901	CAAATACTTTAACATTGCA ATTATTTAAAC CAATTAAAG CGCAATTAA AACAAATTAA CGTGTGAGAAA AAATTGGTAA CGCCGTTTAA CGCCTTGGTC		
	CTCTTAAATA CAAAAGATA GACCGAGATAGGGTGTGAGT GTGTTCCAGT TTGGTACAGA CGTGTGAGA CGACCTACAT TAAAGAACG		
	GGATATTAA GTTTCTTAT CGTGTCTTACACACGAAACGTTACCA CCTACGATTC ACCTCTGTC CGTAGGTGATA ATTCTTGCAC CCTGAGGTG CAGTTCCCG		
	GAAACCCCGT CTATCAGGGAT GTGGCCACACTACAGGAAACCTA TCAAGTGTGTTGGTCGAG TGTCGCTGAA GCACAAATCGGAAACCTAA		
	CTTTTGGCA GATAGTCCCG CTACCGGGTT AGTCTCTTGGTAGTGGGTT AGTCAACAAA CGCCGAGCTT CGTGTGTTAG CGTGTGAGT		
	AGGGAGCCCC CGATTTAGAG CTTGACGGGAAAGCCGGGAAACGTGGCGA GAAAGGAAGG GAAAGAACCG AAAGGAGGG GOGCTAGGOC GCTGGCAAGT		
	TCCCTGGGG GCTAAATCTC GAATCTGCCCC TTCCGGCCGCT TTGCACTGCT CTTCCTTCGCT TTCCCTCGCC CGCGATCCCG CGACGCTTC		
	NheI		
2001	GTAGCGGTCA CGCTGCCGTA AACCACACCA CGCCGCCGCG TTAATCGGCC GCTACAGGGC CGGTGCTAGC CATGTGAGCAAGGCCAG AAAAGGCCAG		
2101	CATCGCCGAT CGCGAGCGCA TTGGTGTGTT GGCGCGCGCAATACGCG CGATGTCGCTG GTACACTCGT TTTCGGCTG TTTCGGCTC		
2201	GAACCGTAAA AAGGGCGCGT TGCTGGTTT TTCCATAGG CTGGCGCCCG CGTACGAGCA TCAACAAAT CGACGGTGA GTGAGGGTGG CGGAAACCCCG		
2301	CTTGGCATTT TTCCGGCGCAACGACCGAA AAAGGTATCC GAGGCGGGGG GACTGCGCTG AGTGTGTTA GCTGCGAGTT CAGTCCTCAC CGCTTGGCG		
2401	ACAGGACTTAAAGGATACCA CGCGCTTCC CGTGGAGGCT CGCCGACTCGC CGCCCTACGGG ATACCTGCGC GCTTCTCTCC		
2501	TGTCTCTGATA TTTCATCTGTT CGCCTAAAGGG CGGACCTTCCGAA CGGAGGACAC GCGTGGGAGC CGCAATGGCC TATGGACAGG CGGAGGAGG		
2601	GGGGCGGAA CGTGTGCGCT TCTCTAGCT CACGGCTGTG GTATGCTAGT CGCGTGGTAGG CGCTGGCTCCTA CGAAGCTGCGC TGTGTGACCG ACGCCCGCTTC		
	TCAGTCCGAC CGCTGCGCT TATCGCGTAA CTATCGCTT GAGTCACCC CGGTAAGACA CGACTTATCG CCACCTGCGAG CAGCCACTGG TAACAGGATT		
	AGTCAGCGT GCGAGCGGAG ATAGGCATT GATAGCAGAA CTACGGGGTGG CGCCATGTTG GCTGAAATCC GTGCGTGGAC ATTGCTCTAA		
	AGCAGCGCA GGTATGTAGCGGTCTACA GAGTTCTGAG AGTGGGGCC TAACTACGGC TACACTAGAA GAAACGATTG TTGGTACTCG GCTCTGCTGT		
	TCGTCGCTGCTTCCATACATCC CGCCACAGTGT CTCAACGACT TCAACACCGG ATTGATGCCG AGTGTGATCT CGTGTGCTAA ACCATAGACG COAGACGACA		
	AGCCAGTTAC CTTCGGAAAAG AGTGTGTTGTA GCTCTGATC CGCCAAACAAACCCCGCTG TGAGCGTGGTTTTGTTGTA CGAAGCGAC AGTATACGGC		
	TCGGTCAATG GAAACCTTTT TCTCAACCAT CGAGAACATAG GCGCTTGTGTT GTGGTGGCGAC CATGCCACC AAAACAAACAA CGCTTCGCG TCTAATCGCG		
	BglII		
2701	AGAAAAAAA GGATCTCAAG AAGATCTTGTATCTTCTGTTG ACGGCTAGTG GAAAGAAAAC TCACGTTAAG GATTTGGT CAGATCTAGC		
2801	GTCTTTTTT CCTAGATTC TTCTAGGAAA CGAGAAGAAGA TGCCCGACAGC TGCGAGTCAC CTTCGTTTG AGTCAATTC CCTAAACACCA GTCTAGATCG		
2901	ACCAGGGGTTTAAGGGCACC ATAACCTGCC TTAAAAAAAT TACCCCGCCG CCTGCGCACTC ATCCGAGTAC TTGTTGAAATT CTTAACGAT TCTGGCGAC		
3001	TGGTCCGCAA ATTCGGCTGG TTATGACGG AAATTCTTAAAT ATGCGGGGGG GGACGGTGGAG TAGGCTCATG ACACATTAAGA GAAATCGTA AGACGGCTGT		
3101	TGGAAACCAT CACAAACGGCA ATGATGACCC TGAATCGCCCG CGGGCATCA CGACCTTGTG CGCTTGGCTGTTAATTTGCACTAGTGAAGAAGCGGAA		
	ACCTTCGCTA GTGTTGGCG TACTACTGG ATTAAGCGGT CGCCGATAGT CGTGGAAACAGC GGACCGATA TTAAAAGCG GTATGTTT TCCCGCCG		
	AGAAGTGTCACTATGGCT ACGTTAAAT CAAACTCGT GAAACTCACC CAGGGATGG CTGAGACAA AAACATATTC TCAATAACCTT TTAGGGAA		
	TCTTCACAG GTATAACCGGA TTGGTGTGACCA CTGGCTTAAAC GACTCTGCTTGTGTTGATAAG AGTATTTGG GAAATCCCTT		
	TATAGCCAGG TTTCACCGT AACACCCAC ATCTTGGAA TATATGTTGAA GAAACGCGG GAAATCGCG TGGTATTCAC TCCAGACGGA TGAAAACGTT		
	TATCCGGTCC AAAAGTGCAGA TTGTCGGCTG TAGAAGCGTT ATATACACAT CTTCGACGC ACCATAAGTG AGGTCCTGCT ACTTTGCAAA		

3201 TCAGTTGCTCATGGAAAC GGTGTAACAA GGGTGAACAT TATCCCATA CACCA GGTCA CGTCTTCATGCCATACG GAACTCCGGG TGAGC/TCA  
AGTCAAACGA GTACCTTGT CCACATTGT CCCACTTGT ATAGGGTATA GTGGTCGAGT GGCAGAAAGT AACGGATG CTTGAGGCC ACTCGTAAGT  
3301 TCAGGGGGC AAGAATGTG AATAAGGCG GATAAAACTT TTGCTTACGG TCTTAAAAAA GGCGTAAATTCAGCTGAA CGGTCTGGT  
AGTCCCGCCG TTCTTACCT TAATTCGGC CTATTITGAA CACGAATAAAAAGAAATGOCAGAAATTTT CCGGCATTAT AGGTCGACTT GCCAGACCA  
3401 ATAGGTACAT TGAGCACTG ACTGAAATCC CTCAAAATGT CTCTTACGAT GCCATTGGGA TATATCAACG GTGGTATATC CAGTGAATT TTCTCCATT  
TATCCATGTA ACTCGTGTAC TGACTTACG GAGTTTACA AGAAATGCTA CGTAAACCTT ATAGTGTG CACCATATAG GTCACTAAM AAAGAGGTAA  
AaII


3501 TTAGCTTCTTAGCTCTGA AAACTCGAT AACTCAAAA ATACGCCCGG TAGTGATCTT ATTTCATTAT GGTGAAAGTT GGAACTCAC CGACGTCTA  
AAATCGAAGGA ATCGAGGACT TTAGAGCTA TTGAGTTTATGCCATCACTAGAA TAAAGTAATA CCACCTTCAA CCTTGGAGTG GGCTGCAGAT  
M13 rev 100.0%

3601 ATGTGAGTTA GTCACCATAGGCAAGGCTTACA CTTATGCTT CGGCTCGTA TGTTGTTGG AAJTGAGGC GGATAACAT TTACACAGG  
TACACTCAAT CGAGTGAGA ATCCGTGGG TCCGAATGT GAAATACGAA GGCGAGCATAACACACC TTAAACACTCG CCTATGTTA AAGTGTGTC  
M13 rev 100.0%

3701 AAAACCTAT GACCATGATT ACGAATTTC AGTATACGAG GCAA AAAAT GAAAAACAGT CTTGTCGCGA TTCCGCTGGT GGTGCCGTC TATAGCCATA  
TTGGTCGATA CTGGTAAAGA TCAATGCTT CCGTTTATA CTTTTGTGAC GACAAGCCT AAGGGACCA CGACGGCAAG ATATCGGTAT  
3801 CGCAGACTG CGACATCGAG TTTCAGAAA CAGTGGAAAG TTGTTAGCA AAACCCATA CAGAAAATTC ATTTCACAC GTCAGGAAAG ACCACAAAC  
CGCTGATGAG GCTGAGCTC AACGCTCTT GTCAACTTCA CGTGTGAGT GAAATGTTAG TAAATGATGTT GTCAGGTTTC TGCTGTTTG  
3901 TTAGATCGT TACCGTAACT ATGAGGGCTG TTGTTGAAATGCTACAGGGT CTTGAGTAAAG TACTGGTAC GAAACTAGT GTTACGGTAC ATGGGTTCT  
AAATCTAGCA ATGCAATTGA TACTCCCGAC AGAACCTTA CGATGTCGAC AACATC/AAC ATGACCACTG CTTGAGTCA CAATGCCATG TACCCAAAGGA  
4001 ATGGGCTTGT CTATCCGAA AAAATGGGT GTGTCGCTG AGGGTGGCGGTTCTGA CGGTGGCTGAAACATC/AAC ATGACCACTG CTTGAGTCA CAATGCCATG  
TAACCCGAAAC GATAGGACT TTACTCCCA CCACCGAGAC TCCCACCGCA AAAGACTCCCA CGCCGAGAC TCCCACCGCATGTTGAA GGACTCATGC  
4101 GTGATCACCG TATCCGGGG TATACCTTA TCAACCCCTCA CGACGGCACT TATCCGCTG GTACTGAGCA AAACCCGCT AAATCTAAATC CTTCCTGAA  
CACTATGTTA ATAAAGCCCA ATATGAAATG ATTTGGGAGA GTGTCGCTGAA TAGGGGGAGA CATGACTCTT TTGGGGCGA TTAGGATTAG GAAGAGACT  
4201 GGAGTCTCAAG CCTCTTAATA CTTCATGTT TCAGAAATAT AGGTCCGAA ATAGG CAGGG GGCATTAACCT GTTACATGCC GCACCTGTAC TCAAGGCACT  
CTTCAGAGTC GGAGAATTAAT GAAAGTACAAAGTCTTATA TCCAAAGGCTT TATCCGTCGCC CGTAAATTGA CAAATATGCC CGTGACAATG AGTTCGCTGA  
4301 GACCCGTTA AAACCTTAA CCAGTACACT CCTGTTACATCAAAGCCAT GTATGA CCTTACTGGAAACG GTAAATICA AGACTGGCT TTCCATTCTG  
CTGGGGCAAT TTGAAATAAT GTTCATGTA GGACATAGTA TTGTTGGTA CATACTGGCA ATGACCTTGC CTTTAAGTC TCTGAOGGA AAAGTAAGAC  
4401 GCTTAAATGA GGATCCATTG TTGTTGAAAT CAAAGGCCA ATCGTCTGAC CTGCTCAAC CTCCTGCAA TGCTGGCGC GGCTCTGGTG GTGGTCTG  
CGAAATTACT CCTAGGTAAAGCAACCTTA TAGTTCCGGT TAGCAGACTG GACGGAGTTG GAGGACAGT ACGACCCCG CGAGACCCAC CACCAAGAC  
4501 TGCGGGCTCT GAGGGGGCG GCTCTGAGGG TTGGGGCTCT GAGGGTGGCG GCTCTGAGGG TTGGCGCTTC GGTTGGGGCT CGGGTTGG TGATTTGA  
ACCGCGAGA CTCCACCGC CGAGACTOCC ACCGCCAAGA CTCCACCGC CGAGACCTCC ACCGCCAAGG CCACCCGCCA GGCCAAGGCC ACTAAAATCA  
4601 TATGAAAAAA TTGCAACGC TAATAAGGG GTATGACCG AAAATGCCA TGAAAACCGG CTACAGTCTG ACGCTAAAGTGAAACTGTAT GTGTCGCTA  
ATACCTTTT ACCGGTTCGCA ATTATCCCG CAGACTGCT TTGTTGGCT ACCTTTGC CAGTGTAGAC TCGCAATTCCGTTGAACTA AGACAGCGAT  
4701 CTGATTCAGG TGCTGCTATGGATGGTTCA TTGGTGACGT TTCCGGCTT GTAAAGGTAA ATGGTGCTACTGGTATTGTT GTGGCCTA ATCCCAAAT  
GACTAATGCC ACAGATAG CTACCAAGT AACCACTGCA AAGGCCGA CGATTACCAT TACCCAGATG ACCACAAAA CGACGGAGAT TAAGGGTTA  
4801 GGCTCAAGTC GGTAGGGTG ATAATTCACC TTAAATGAAAT ATTTCCGCTAATAATTTACCTCTTGGCT CAGTCGGTTG ATGTCCCCC TTATGCTTT  
CCGAGTTCAAGCTTACCTGCACT TATAAAGTGG AAATTCACCTTA TAAAGGCAG TTAAATGG AAGAACCGGA GTACGCCAC TTACAGGGG AATACAGAAA  
4901 GGCCTGTTA AACCATATGA ATTTCATGAA GATGTTGACA AAATAACAT ATTCCTGTTGCTTGTCTTGTAT TGTGTCGCTTGGGGGG  
CCGCACCAT TTGGTATACTTTAAAGATAA CTAAACACTGT TTGTTGAA TAAGGCCACCAAGAAACCA AAGAAAATAT ACAACGGTGG AAATACATAC  
XbaII

AII

5001 TATTTGCACTTACATCTGCA ATAAGGAGTC TTAAAGTAAT  
ATAAAAGCTG CAAACGATTG TATGACGCTT TATCCTCAAG AATTCTTAA




**Figure 3: Quantitative analysis of the mean display rate of Fab on phages by anti-gIIIp Western blot:**

Fd-gIIIct/wtgIIIp:  $1.25 \times 10^8$  phage :  $2 \times 10^7$  phage = 6.25


$\Rightarrow 1$  Fd-gIIIct per 6.25 wtgIIIp = 1 Fd-gIIIct per 1.25 phage (5 wtgIIIp per phage)

$\Rightarrow$  mean number of Fab per phage: 0.8



**FIGURES - 4A and 4B**


**Figure 4C** is a Vector map for pMorph13 scFv Mac1-5




**Figure 4D** is the nucleic acid sequence encoding vector pMorph13 scFv Mac1-5

**Display determination of dicistronic scFv CysDisplay vector (pMORPH20):**

**pMORPH20\_C\_gIII\_Mac1\_LHC (VL lambda pool)**




**pMORPH20\_C\_gIII\_Mac1\_LHC (VL kappa pool)**



Figs 5A & 5B

**Figure 5 C: Vector map pMorph20 Mac1-5**



### **Figure 5 D: DNA sequence pMorph20 Mac1-5**

gttttcatgcatacggaaactccgggtgagcattcatcaggcggcaagaatgtgaataaaggccggataaaactt  
gtgcattttttcttacggcttaaaaaggccgtaatatccagctgaacggctggttataggtagtacattgagcaactga  
ctgaaatgcctcaaaatgttcttacgatgccattggatatatcaacgggttatatccagtgatttttctccatttttag  
cttocttagctcgtaaaatctogataactcaaaaaatacgcccggtagtgatcttatttcattatggtaaagtggAAC  
ctcacccgacgtctaattgtgagttagctcactcattaggcacccaggcttacactttatgctccggctcgtatgttg  
tggaaattgtgagccgataacaatttca**cacagggaaacagctatgaccatgattacgaattt**


Display determination of dicistronic Fab vector (pMORPH18; conventional display):

Figs 6A & 6B


**pMorph18\_Fab\_Mac1-5 (VH2 lambda1)**



**pMorph18\_Fab\_Mac1\_A8 (VH3 kappa1)**



**Figure 6C: Vector map of pMORPH®18-Fab Mac1-5**



**Figure 6 D: DNA sequence of pMORPH®18-Fab Mac1-5**


Figs 7A & 7B

Display determination of dicistronic Fab CysDisplay vector (pMORPHX10 + pBR\_C\_gIII; 2-vector system):

**pMORPHX10\_Mac1\_A8\_VL\_LHC\_VH\_FS + pBR\_C\_gIII (VH3 kappa1)**



**pMORPHX10\_Mac1-5\_VL\_LHC\_VH\_FS + pBR\_C\_gIII (VH2 lambda1)**



**Figure 7C** is the vector map for pMORPHX10 Fab Mac1-5 VL LHC VH FS





Figure 7D is the nucleic acid sequence for pMORPHX10 Fab Mac1-5 VL LHC VH FS

cagcagttccccggacggcgccaaactgctgattatgataacaaccagcgtccctcaggcgtccggatcggttagcggatc  
caaaaagcgcaccagcgcgagcccttgcgattacgggcctgcaagcgaagacgaagcggattattatggccagagctatgacca  
gaatgctcttgtgagggtttggcgccggcacgaagttaaccgttggccagccgaaagccgaccgcgactgtgacgctgtttcc  
gccgagcagcgaagaattgcaggcgaacaagcgaaccctgggtgcctgattagcactttatccggagccgtgacagtgcc  
tggaggcagatagcagccccgtcaaggcgggagtggagaccaccacccctccaaacaagcaacaacaagtcacgcggcc  
cagctatctgagcgtccctgacgcgtcagtgaaagtccacagaagctacagctgcccaggcgtacgcgtcatgaggggagcacc  
aaaaaccgttgcgcgactgaggcctccagggggagcggaggcgcgcaccatcatcaccatcactgctgataataatgca  
tgcgttaggagaaaataaaaa taaaacaaagcactattgcactggcacttaccgttgccttccatccctgttaccaagcc  
caatgaaagaaaagcggcccgcccttgtaaaccgaccctgaccctgacccttccggatgttgccttcc  
tctggcgttggcggtggctggattcgccagccctggaaagccctcgagtggtggctctgattgattggatgatgataatgat  
tatagcaccagccctgaaaacgcgtctgaccattagcaaagaatctcgaaaaatcagggtgtgactatgaccaacatggaccc  
ggggatacggccaccttattgcgcgtttgtatcctttttgttatttggggccaaggcaccctgggtgacgg  
agctcagcgtcacccttggcggcccttgtaaaccgaccctgaccctgagctggaaacagcggggcgtgaccagcggcgt  
gcctggtaaagattattcccgaaaccagtccctgtggcggctgggggggggggggggggggggggggggggggggg  
gtgtcgtcaaagcagcggccgtgtatagcctgagcagcgttgcgttgcggagcagcgttggcactcagactatatttca  
cgtgaaccataaaccggacacacccaaagtggataaaaaagcggaaaagcgaattcactataaagaatgacgatgacca  
aggcgcggccgtggagccaccctcgagttggaaaatgataagcgttgcactgtgaaatggcgagattgtgcacatttt  
tttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgtt  
tcgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgtt  
gatagggttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgtt  
atcaggcgtatggccactacgcggacaccatcaccctaatcaagtttttgggtgcgggggggggggggggggggg  
aaaggagcccccgtttagagcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgtt  
ggcgttagggcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgtt  
gcttagactgtttaaaccggaccgg  
gggttagcctcaactcccgcttcccgatcgtggaaaacctgtcgttgcgttgcgttgcgttgcgttgcgtt  
tttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgtt  
ttcgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgtt  
atctgatcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgtt  
atcgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgtt  
atcgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgtt  
aacttaatggggccatcaccggcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgtt  
gagaaaataactgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgtt  
tagcatcctggcatcccgatcaccggcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgtt  
gacgcggccgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgtt  
cgctgtcaggggccactgg  
aattcagctcccccattcccgatcgttgcgttgcgttgcgttgcgttgcgttgcgtt  
ataagagacaccggcataactctgcgtatcgacacaccacacccgttgcgttgcgttgcgtt  
atgcctaccggcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgtt  
ccgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgtt  
acaggactataagataccaggcgttgcgttgcgttgcgttgcgtt  
cgcccttcccccgttgcgttgcgttgcgttgcgttgcgttgcgtt  
gctgtgtcacaaccggccatcgttgcgttgcgttgcgttgcgtt  
atcgccactggcagcggccactggtaacaggatttcgttgcgtt  
aactacggctacactagaagaaacagtatttgcgttgcgtt  
ccggcaaaacccaccggctgttgcgttgcgttgcgtt  
ccttgcgttgcgttgcgttgcgttgcgttgcgtt  
gggcaccaataactgcctaaaaattacgcgttgcgtt  
ggaagccatcacaacccggcatgttgcgttgcgtt  
aaacggggggcgaagaatgttgcgttgcgtt  
catattctcaataaccctttagggaaatggccagg  
aaatcgtgttgcgttgcgttgcgttgcgtt  
aaatcgtgttgcgttgcgttgcgttgcgtt  
aaatcgtgttgcgttgcgttgcgttgcgtt  
ctgaaaatctcgataactaaaaatcgcgttgcgtt  
gagttgcgttgcgttgcgttgcgttgcgtt  
acacaggaaacagctatgaccatgattctgat  
acaacggggcaaaaaatgaaaacag  
acagctatcgcgttgcgtt

gcactggctggttcgctaccgttagcgcaggccgatatcgctgacccagccgccttcagtgagtggtgcaccagg**t****c**agcgtgt  
gaccatctcgtagcggcagcagcaacattggcagcaactatgtgagctggta


**Figure 7E** is the vector map for pMORPHX10 Fab Mac1-5 VL VH LHC



**Figure 7F** is the nucleic acid sequence for pMORPHX10 Fab Mac1-5 VL VH LHC

**cgccaatcagcaacgactgttgcggccagtgttgtgccacgcggtaggaatgtaaattcagctccgccatcgccgttccactttt  
tccccgcgtttcgcagaaaacgtggctggctgttcaccacgcggaaacggctgataagagacaccggcatactct**

Figure 7G is the vector map for pBR-C-gIII



**Figure 7H** is the nucleic acid sequence for pBR-C-gIII.

tcctgttaccagtggctgccagtggcgataagtcgtgtcttaccgggttgactcaagacgatagttaccggataaggcgcagc  
ggtcgggctgaacgggggttcgtcacacagccagcttggagcgaacgacctacaccgaactgagatacc tacagcgtgagct  
atgagaaagcgcacgcgttccgaagggagaaggcggacaggatccggtaagcgcagggtcggAACAGGAGAGCGCACG  
AGGGAGCTTCCAGGGGGAAACGCCCTGTATCTTATAGTCCTGTCGGGTTCCGCACCTGACTGAGCGTCGATTTGTGATGCTC  
GTCAGGGGGCGGAGCCTATGAAAAACGCCAGCAACGCCGCTTTACGGTCCTGCCCTTGCTGGCCTTGCTCACATGTC  
TTTCCTGCGTTATCCCCTGATTCTGTGGATAACC GTATTACCGCCTTGAGTGAGCTGATACCGCTCGCCG CAGCCGAACGACCGAGC  
GCAGCGAGTCAGTGAGCGAGGAAGCGGAAGAGCGCCTGATCGGTATTTCTCCTACGATCTGTGCGGTATTCACACCGCATAT  
GGTCACCTCTCAGTACAATCTGCTCTGCGCATAGTTAACGCGTATAACACTCCGCTATCGCTACGTGACTGGGTATGGCTGCG  
CCCCGACACCCGCCAACACCCGCTGACGCCCTGACGGGCTGTCTGCTCCGGCATCCGTTACAGA

Figs 8A & 8B

Display determination of tricistronic Fab CysDisplay vector (pMORPH23 or pMORPH24; one-vector system):

**pMORPH23\_VH3\_V $\kappa$ + $\lambda$  (pool)**



**pMORPH23\_VH2\_V $\kappa$ + $\lambda$  (pool)**




Figure 9

